When Does Nurtec Go Generic?

What Is Nurtec ODT and Why Does Patent Expiration Matter?

Nurtec ODT (rimegepant) is a prescription medication used to treat and prevent migraine attacks in adults. It belongs to a newer class of drugs called CGRP receptor antagonists, which work by blocking a protein involved in migraine pain and inflammation.

Patent protection gives the original drug manufacturer exclusive rights to produce and sell the medication for a specific period. During this time, no generic versions can enter the market. Once patents expire, other pharmaceutical companies can create generic versions, which typically cost much less than brand-name drugs.

For patients taking Nurtec ODT regularly for migraine prevention or treatment, understanding when generic options might become available can help with long-term financial planning and medication access.

When Does the Nurtec Patent Expire?

The primary patent for Nurtec ODT (rimegepant) is scheduled to expire in 2039. This means generic versions of rimegepant would not be available for another 13 years, assuming no patent extensions or legal challenges delay the timeline.

However, patent expiration dates can change due to several factors:

• Patent extensions: The FDA may grant additional patent protection if the manufacturer meets certain criteria.
• Secondary patents: Additional patents on manufacturing processes or formulations could extend exclusivity.
• Legal challenges: Patent disputes between companies can delay generic entry.
• Regulatory approval: Generic manufacturers must complete their own FDA approval process.

What Affects the Generic Drug Availability Timeline?

Even after patents expire, generic versions do not automatically appear on pharmacy shelves. Generic drug manufacturers must file an Abbreviated New Drug Application (ANDA) with the FDA and demonstrate that their version is bioequivalent to the original medication.

This approval process typically takes several months to over a year. Generic manufacturers often begin preparing their applications before patent expiration to minimize delays once exclusivity ends.

Current Patent Status and Market Exclusivity

Nurtec ODT currently enjoys patent protection through multiple intellectual property rights. The medication was originally developed by Biohaven Pharmaceuticals, which was later acquired by Pfizer through a strategic collaboration agreement.

Patent protection includes the active ingredient rimegepant as well as the specific orally disintegrating tablet (ODT) formulation. The ODT formulation allows the medication to dissolve on the tongue without water, which provides convenience for migraine sufferers who may experience nausea.

Understanding Drug Patent Types

Pharmaceutical patents typically fall into several categories:

• Composition of matter patents: Cover the active ingredient itself.
• Formulation patents: Protect specific ways the drug is prepared or delivered.
• Method of use patents: Cover specific medical uses or dosing regimens.
• Process patents: Protect manufacturing methods.

Nurtec ODT may be protected by multiple patent types, and each could have different expiration dates that affect when generics become available.

What to Expect When Nurtec Goes Generic

When generic rimegepant becomes available, patients can expect several changes in the medication landscape:

Price Reduction

Generic medications typically cost 80 to 85 percent less than brand-name versions once multiple generic manufacturers enter the market. Initial generic versions may offer more modest savings, with prices dropping further as competition increases.

Multiple Generic Options

Several pharmaceutical companies may produce generic rimegepant once patents expire. Each generic version must meet the same FDA standards for safety, effectiveness, and quality as the original brand-name medication.

Insurance Coverage Changes

Many insurance plans prefer generic medications when available. Once generic rimegepant enters the market, some insurers may require patients to try the generic version before covering the brand-name medication, or they may place the brand name on higher cost-sharing tiers.

Current Cost-Saving Options for Nurtec ODT

While waiting for generic versions, patients have several options to reduce Nurtec ODT costs:

Patient Assistance Programs

The manufacturer offers patient assistance programs that may reduce out-of-pocket costs for eligible patients. These programs typically have income requirements and may not be available to patients with government insurance.

Insurance Coverage and Prior Authorization

Many insurance plans require prior authorization for Nurtec ODT, meaning doctors must demonstrate medical necessity before coverage is approved. ⁵ Working with your healthcare provider to complete this process can help ensure coverage.

Cash Pay Options

For patients without insurance coverage or those facing high copays, paying cash through reliable pharmacy options may provide cost savings. Exploring different pharmacy pricing can help identify the most affordable cash-pay options while ensuring medication safety and authenticity.

Alternative Medications to Consider

While waiting for generic Nurtec ODT, patients may want to discuss alternative migraine treatments with their healthcare providers:

Other CGRP Receptor Antagonists

Several other medications in the same class as Nurtec ODT are available, including Ubrelvy (ubrogepant) and Qulipta (atogepant). These medications work similarly but may have different patent expiration timelines.

CGRP Monoclonal Antibodies

Injectable CGRP inhibitors like Aimovig, Emgality, and Ajovy offer migraine prevention but require monthly or quarterly injections rather than oral dosing.

Traditional Migraine Medications

Older migraine treatments, including triptans like Zomig and preventive medications like beta-blockers or anticonvulsants, may be more affordable and could provide effective alternatives for some patients.

Planning for Generic Availability

Patients currently taking Nurtec ODT can take several steps to prepare for eventual generic availability:

Stay Informed About Patent Updates

Patent expiration dates can change due to legal challenges or regulatory decisions. Staying informed through reliable health information sources can help patients plan accordingly.

Discuss Long-Term Treatment Plans

Working with healthcare providers to develop comprehensive migraine management plans ensures patients have alternatives if medication access or costs change.

Monitor Insurance Coverage Changes

Insurance formularies change annually. Patients should review their coverage during open enrollment periods and understand how generic availability might affect their benefits.

Key Takeaways About Nurtec Generic Timeline

Understanding when Nurtec ODT goes generic helps patients plan for long-term migraine management:

• Patent expiration: Currently scheduled for January 27, 2032.
• Timeline uncertainty: Patent extensions or legal challenges could delay generic availability.
• Cost benefits: Generic versions typically offer significant cost savings.
• Current options: Patient assistance programs and cash-pay alternatives can help reduce current costs.
• Treatment planning: Working with healthcare providers ensures continuity of care regardless of generic availability.

While generic rimegepant is still years away, patients dealing with migraine and other health conditions can explore current cost-saving options and work with their healthcare teams to develop sustainable treatment approaches.

As the pharmaceutical landscape continues to evolve, staying informed about patent timelines, insurance changes, and alternative treatments helps ensure continued access to effective migraine management options.

References

• Nurtec ODT Patent Expiration. Pharsight GreyB. Accessed April 4, 2026.
• Nurtec ODT Drug Patent Watch. Drug Patent Watch. Accessed April 4, 2026.
• Biohaven and Pfizer Enter Strategic Collaboration. Pfizer. Accessed April 4, 2026.
• Prior Authorization Medical Necessity Migraine Medications. UnitedHealthcare. Accessed April 4, 2026.
• Nurtec ODT (rimegepant) orally disintegrating tablets, for sublingual or oral use [Prescribing Information]. Pfizer. Last updated 3/2026. Accessed April 4, 2026.